GlaxoSmithKline (NYSE: GSK) acquired the HIV portfolio from Bristol-Myers Squibb (NYSE: BMY). Both sides announced the preliminary deal in December. GSK pays $350 million up front and could pay an additional $1 billion depending on developmental and sales milestones.
{iframe}http://www.bizjournals.com/triangle/news/2016/02/22/gsk-acquires-bristol-myers-hiv-portfolio-for-350m.html{/iframe}